Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows
Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, double-blind, placebo-controlled study, called SOLO-1 (NCT01844986), assessed Lynparza as a maintenance therapy for patients with advanced ovarian cancer, who had a BRCA mutation in their

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *